anti-doping testing comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-05-18. Where a claim depends on a specific study, the study is described rather than over-claimed.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Investigational status in most countries |
| Sports status | Prohibited by WADA | Classified as non-approved or metabolic modulator |
| Common analytical method | LC-MS/MS | Used for trace detection in biological samples |
| Typical test matrices | Urine and blood | Sample choice depends on testing program |
| Human trial data | None published | Effects and safety are not established |
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
==== Interpretation of results ==== HOMA-IR < 2: normal insulin sensitivity HOMA-IR > 2: possible insulin resistance HOMA-IR > 2,5: probable insulin resistance HOMA-IR > 5: typical results for type 2 diabetes SPINA-GR 1,41–9,00 mol/s: normal insulin sensitivity SPINA-GR ≤ 1,40 mol/s: insulin resistance SPINA-GR < 1,35 mol/s: typical results for type 2 diabetes
=== Conservation and sustainability === E. longifolia is mainly used for its roots, which necessitates uprooting the entire plant when it is harvested. This has led to concerns over the long-term sustainability of its use. In Malaysia raw E. longifolia is banned from export, and the plant itself been listed as one of the priority species for conservation, and the harvesting of wild trees is restricted according to Act 686 on International Trade in Endangered Species. In 2016, Ahmad Shabery Cheek, the Malaysian Minister of Agriculture, said that the species may go extinct within twenty years if cultivation and replanting efforts are not made quickly. To support commercialization, the Malaysian government made attempts to encourage the long-term commercial cultivation of the plant, through the provision of grants for farmers, enabling agronomy research by MARDI, and the formation of cluster farms under the East Coast Economic Region.
A level of <70 mg/dL (<3.8 mmol/L) is described as a hypoglycemic attack (low blood sugar). Most diabetics know when they are hypoglycemic and seek food or a sweet drink to raise their glucose levels. Intensive efforts to achieve blood sugar levels close to normal have been shown to triple the risk of the most severe form of hypoglycemia, in which the person requires assistance from by-standers in order to treat the episode. Among intensively controlled type 1 diabetics, 55% of episodes of severe hypoglycemia occur during sleep, and 6% of all deaths in diabetics under the age of 40 are from hypoglycemia at night. Hypoglycemia can be problematic if it occurs while driving as it can affect a person's thinking process, coordination, and state of consciousness. Some people are more prone to hypoglycemia as they have reported fewer warning symptoms, and their body released less epinephrine (a hormone that helps raise blood glucose). Additionally, individuals with a history of hypoglycemia-related driving mishaps appear to use sugar at a faster rate. Drivers with diabetes susceptible to driving mishaps should monitor their blood sugar to be not less than 70 mg/dL (3.9 mmol/L). Instead, these drivers are advised to treat hypoglycemia and delay driving until their blood glucose is above 90 mg/dL (5 mmol/L).
Sources: en.wikipedia.org
1883. A Treatise on the Motion of Vortex Rings: An essay to which the Adams Prize was adjudged in 1882, in the University of Cambridge. London: Macmillan and Co., pp. 146. Recent reprint: ISBN 0-543-95696-2. 1888. Applications of Dynamics to Physics and Chemistry. London: Macmillan and Co., pp. 326. Recent reprint: ISBN 1-4021-8397-6. 1893. Notes on recent researches in electricity and magnetism: intended as a sequel to Professor Clerk-Maxwell's 'Treatise on Electricity and Magnetism'. Oxford University Press, pp. xvi & 578. 1991, Cornell University Monograph: ISBN 1-4297-4053-1. Thomson, Joseph John (1893). Notes on recent researches in electricity and magnetism. Oxford: Clarendon Press. Thomson, Joseph John (1900). Discharge of electricity through gases (in German). Leipzig: Johann Ambrosius Barth. Thomson, Joseph John (1904). Electricity and matter (in English). Oxford : Clarendon Press. Thomson, Joseph John (1905). Electricity and matter (in Italian). Milano: Hoepli. Thomson, Joseph John (1908). Corpuscular theory of matter (in German). Braunschweig: Vieweg und Sohn. 1921 (1895). Elements of the Mathematical Theory of Electricity And Magnetism. London: Macmillan and Co. Scan of 1895 edition. A Text book of Physics in Five Volumes, co-authored with J.H. Poynting: (1) Properties of Matter, (2) Sound, (3) Heat, (4) Light, and (5) Electricity and Magnetism. Dated 1901 and later, and with revised later editions. Dahl, Per F. (1997). Flash of the Cathode Rays: A History of J J Thomson's Electron. Bristol and Philadelphia: Institute of Physics Publishing. ISBN 0-7503-0453-7.
== Pharmacokinetics == Loop diuretics are highly protein bound and therefore have a low volume of distribution. The protein bound nature of the loop diuretic molecules causes it to be secreted via several transporter molecules along the luminal wall of the proximal convoluted tubules to be able to exert its function. Loop diuretics usually have a ceiling effect whereby doses greater than a certain maximum amount will not increase the clinical effect of the drug. Also, there is a threshold minimum concentration of loop diuretics that needs to be achieved at the thick ascending limb to enable the onset of abrupt diuresis. The availability of furosemide is highly variable, ranging from 10% to 90%. The biological half-life of furosemide is limited by absorption from the gastrointestinal tract into the bloodstream. The apparent half-life of its excretion is higher than the apparent half-life of absorption via the oral route. Therefore, furosemide taken intravenously is twice as potent as an equivalent dose taken orally. However, for torsemide and bumetanide, their oral bioavailability is consistently higher than 90%. Torsemide has a longer half life in heart failure patients (6 hours) than furosemide (2.7 hours). A 40 mg dose of furosemide is clinically equivalent to a 20 mg dose of torsemide and to a 1 mg dose of bumetanide.
Strontium is a divalent silvery metal with a pale yellow tint whose properties are mostly intermediate between and similar to those of its group neighbors calcium and barium. It is softer than calcium and harder than barium. Its melting (777 °C) and boiling (1377 °C) points are lower than those of calcium (842 °C and 1484 °C respectively); barium continues this downward trend in the melting point (727 °C), but not in the boiling point (1900 °C). The density of strontium (2.64 g/cm3) is similarly intermediate between those of calcium (1.54 g/cm3) and barium (3.594 g/cm3). Three allotropes of metallic strontium exist, with transition points at 235 and 540 °C. The standard electrode potential for the Sr(2+)/Sr couple is −2.89 V, approximately midway between those of the Ca(2+)/Ca (−2.84 V) and Ba(2+)/Ba (−2.92 V) couples, and close to those of the neighboring alkali metals. Strontium is intermediate between calcium and barium in its reactivity toward water, with which it reacts on contact to produce strontium hydroxide and hydrogen gas. Strontium metal burns in air to produce both strontium oxide and strontium nitride, but since it does not react with nitrogen below 380 °C, at room temperature it forms only the oxide spontaneously. Besides the simple oxide SrO, the peroxide SrO2 can be made by direct oxidation of strontium metal under a high pressure of oxygen, and there is some evidence for a yellow superoxide Sr(O2)2. Strontium hydroxide, Sr(OH)2, is a strong base, though it is not as strong as the hydroxides of barium or the alkali metals.
MCAS is generally considered a diagnosis of exclusion, meaning that other potential diagnoses must be ruled out before it is applied. Given a diagnosis of MCAS as described above, various subclassifications of MCAS have been proposed depending on the presence of specific pathologies or triggers. MCAS may be considered primary (if KIT genetic mutations or clonal MCs in bone marrow are detected), secondary (if IgE-mediated or non-IgE-mediated allergy mechanisms are present), combined (involving multiple variants), or idiopathic (if specific causes cannot be identified). There is debate over whether HαT, a genetic trait involving copies of the TPSAB1 gene which encodes for alpha-tryptase, should be considered a modifying factor that influences mediator-related symptoms or an initiator for a subcategory of MCAS.
Sources: en.wikipedia.org
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.
Sports authorities prohibit it because it is not approved for human use and has potential performance-enhancing effects. It appears on anti-doping lists under non-approved or metabolic modulator categories.
Detection usually uses liquid chromatography-tandem mass spectrometry. The method targets the parent compound or its metabolites in urine or blood.
It is usually detected by LC-MS or HPLC-UV against a reference standard. In biological matrices, metabolite targeting can improve detection. No universal immunoassay is widely available.